A small study involving Keytruda (pembrolizumab) showed that the cancer drug has been effective in shrinking or removing cancer tumors. With this, the U.S. Food and Drug Administration immediately approved the drug for patients with locally advanced or metastatic urothelial carcinoma.
The Keytruda is the first drug that has been approved for treating tumors that share a certain genetic profile, and thousands of patients are expected to benefit from it every year, according to The New York Times. Even without a control group, or a set of patients that did not receive the drug to compare with, the results are compelling and convincing.
The study, originally released in the Science journal, saw eighty-six patients participating in the trial. Sixty-six of them had tumors that shrank significantly. Among the 66 patients, 18 patients had their tumors disappeared.
Dr. Jack Jacoub, a medical oncologist at MemorialCare Cancer Institute, said that the results of the study, which was published in the journal Science last week, showed the effectiveness of targeting the immune system to treat cancer. This is in contrast to the common classification of cancers based on their location in the body. With pembrolizumab, the cancer cells are unmasked so that the immune system can identify and destroy them.
Keytruda is made by Merck & Co. and costs around $156,000 a year for patients with advanced lung, melanoma and bladder tumors. The study is ongoing, and the drug maker has also begun a trial to pair Keytruda with CTLA4 candidate MK-1308, per FiercePharma.
Merck hosted an encouraging analyst meeting at ASCO last week, and Morgan Stanley remains bullish on growth prospects of its new cancer drug. The Keytruda is the main catalyst for the company’s stock this year, which Zacks Investment Research rated “buy” in a research note published on May 26, according to a report from Smart Stock News.
IgG Antibodies to SARS-CoV-2 Acquired after Natural Infection are Maintained Beyond 12 Months
A seropersistence study shows that IgG antibodies generated after natural infection are maintained beyond 12 months. This study reveals that...
DIA Unveils the Group’s First Sustainability Plan
DIA Group has announced its sustainability plan. It is based on 15 lines of action grouped into three categories: environmental...
What’s Next, Inflation or Deflation? What Does it Mean for the Markets?
The credit markets should be freezing up and the stock market should be plunging from record-high valuations by that time....
Five Important Questions to Ask Before Investing in Gold
Before investing in gold, you should due your diligence in order to make wise choices. The question of whether your...
As Inflation Fears Deepen, Stablecoins Become Irresistible
With the consumer price index rising and the purchasing power of the U.S. dollar on the decline, people are seeking...
Featured7 days ago
Finlombarda Invests 1.5 Million in a Fund Promoted by P2P Lending October to Finance SMEs in Lombardy
Crowdfunding7 days ago
DeFi Projects Raised $200 Million in 2020 and $1 Billion since 2017
Africa7 days ago
Entrepreneurship: the Region Laâyoune-Sakia El Hamra Launches the Program RIYADA
Crypto7 days ago
Dirham Project: the World’s First Regulated Stable Currency